Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-28 21:06:05 - browse：3

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Arena BioWorks launches in Cambridge to speed drug discovery

WSS

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

American taxpayers paid $1.8 trillion in health care costs in 2022

Medicare Advantage coverage denials need scrutiny, senators say

Medicare’s new pay boost for primary care is angering specialists

Study suggests Covid rebound is far more common with Paxlovid than without

Stories you might have missed in 2023: health, science, medicine

knowledge

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Hollywood unions extend contract negotiations for actors

JPM pitch from hospitals? Revenue streams outside of patient care

Psychedelics group wrestles with new pharma identity

NIH chief: government has fallen behind pharma on clinical trials

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Carbon Health diabetes program, a test of data

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Healthy food access boosts outcomes in two studies

Peter Hotez and the public health issue of online harassment

Weight loss drugs should be covered by insurers, AMA says

explore

JPM pitch from hospitals? Revenue streams outside of patient care

Study suggests new cause of Down syndrome: cells linked to aging

Medicare Advantage coverage denials need scrutiny, senators say

Publishing genetic code of viruses could cause disaster

Medicare’s new pay boost for primary care is angering specialists

Boston Scientific acquires urology company Axonics for $3.7 billion

focus

knowledge

knowledge

entertainment